Stockscreener 앱 받기
2.07
5.05%
-0.11
시간 외 거래:
2.05
-0.02
-0.97%
전일 마감가:
$2.18
열려 있는:
$2.18
하루 거래량:
410.18K
Relative Volume:
0.07
시가총액:
$7.31M
수익:
-
순이익/손실:
$-23.42M
주가수익비율:
-0.0265
EPS:
-78
순현금흐름:
$-16.67M
1주 성능:
-14.46%
1개월 성능:
+97.14%
6개월 성능:
-52.19%
1년 성능:
-87.10%
1일 변동 폭
$2.05
$2.1899
1주일 범위
$2.02
$2.60
52주 변동 폭
$0.8926
$24.00
Mustang Bio Inc Stock (MBIO) Company Profile
명칭
Mustang Bio Inc
전화
(781) 652-4500
주소
377 PLANTATION STREET, WORCESTER, NY
MBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
2.07 | 10.59M | 0 | -23.42M | -16.67M | -78.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2020-10-02 | 개시 | B. Riley FBR | Buy |
| 2019-11-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-08-13 | 개시 | H.C. Wainwright | Buy |
| 2019-06-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 개시 | Oppenheimer | Outperform |
모두보기
Mustang Bio Inc 주식(MBIO)의 최신 뉴스
Mustang Bio Inc. Stock Analysis and ForecastFree Stock Selection - Autocar Professional
What drives Mustang Bio Inc. stock priceFree Stock Market Trend Analysis - PrintWeekIndia
What analysts say about Mustang Bio Inc. stockOverwhelming financial success - jammulinksnews.com
Is Mustang Bio Inc. a good long term investmentBreakthrough wealth creation - jammulinksnews.com
Mustang Bio (NASDAQ:MBIO) Upgraded to “Hold” at Wall Street Zen - Defense World
How Mustang Bio Inc. stock performs during market volatility200 Percent Gain Alert - Newser
Why Mustang Bio Inc. stock attracts strong analyst attentionSafe Entry High Exit Alerts - Newser
What makes Mustang Bio Inc. stock price move sharplyTriple Digit Return Forecasts - Newser
MBIO Stock: Exploring Mustang Bio Inc’s Growth - investchronicle.com
Mustang Bio Shares Skyrocket After Orphan Drug Designation - StocksToTrade
Mustang Bio’s Shares Skyrocket as FDA Grants Orphan Drug Designation - timothysykes.com
Promising Small Cap Stocks Worth Watching – July 7th - Defense World
Top Penny Stocks To Follow Now – July 7th - Defense World
Mustang Bio’s Meteoric Surge: What’s Driving Up MBIO? - StocksToTrade
Mustang Bio’s Stock Soars: What’s Driving the Surge? - timothysykes.com
Mustang Bio Receives FDA Orphan Drug Designation - TipRanks
Best Medical Stocks To Follow Today – July 7th - Defense World
Promising Pharmaceutical Stocks To Consider – July 7th - Defense World
Top Biotech Stocks To Research – July 7th - Defense World
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On - Benzinga
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - TradingView
Mustang Bio Stock Jumps 180% After FDA Grants Orphan Drug Status to Brain Cancer Drug - inkl
Why Did Mustang Bio Plunge 11.68% After 196.21% Surge? - AInvest
Market Wrap | US Stocks Slide as Fed Rate Cut Hints Emerge Palantir and Mustang Bio Soar - AInvest
Mustang Bio (MBIO) Stock Explodes 260% After FDA Grants Key Cancer Drug Designation - Benzinga
Dow Dips 1%; Mustang Bio Shares Spike Higher - inkl
Biotech Stock Analysis: MBIO Soars after FDA Grants Orphan Drug Designation - Markets.com
This BlackRock stock just spiked over 300% - Finbold
Mustang Bio Stock Surges: Time to Reconsider? - StocksToTrade
FDA grants orphan drug status to Mustang Bio’s glioma treatment By Investing.com - Investing.com Canada
Mustang Bio’s Drastic Turn: Opportunity or Red Flag? - timothysykes.com
Mustang Bio rises after FDA orphan drug status for MB-101 - Seeking Alpha
Mustang Bio stock soars after FDA grants orphan drug designation By Investing.com - Investing.com South Africa
Mustang Bio stock soars after FDA grants orphan drug designation - Investing.com
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma - The Manila Times
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
Breakthrough Brain Cancer Treatment: FDA Backs Mustang Bio Therapy After 66-Month Complete Response in Trials - Stock Titan
Mustang Bio Plunges 25.37% Amid Reverse Split, Financial Woes - AInvest
Mustang Bio (NASDAQ:MBIO) Shares Down 5.1% – What’s Next? - Defense World
ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress - insights.citeline.com
Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews
Why MongoDB Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
CAR T Cell Therapy Market Projected to Witness Massive Growth - openPR.com
Mustang Bio Inc (MBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):